TY - JOUR
TI - European League against Rheumatism (EULAR) recommendations and EULAR/American College of Rheumatology criteria - Documenting progress in lupus
AU - Aringer, M.
AU - Tektonidou, M.G.
AU - Boumpas, D.
AU - Houssiau, F.
JO - Rheumatology (United Kingdom)
PY - 2021
VL - 60
TODO - 6
SP - 2976-2978
PB - Oxford University Press
SN - null
TODO - 10.1093/rheumatology/keaa672
TODO - angiotensin receptor antagonist;  anifrolumab;  autoantibody;  azathioprine;  belimumab;  beta2 glycoprotein 1 antibody;  cardiolipin antibody;  dipeptidyl carboxypeptidase inhibitor;  DNA;  glucocorticoid;  hydroxychloroquine;  immunomodulating agent;  immunosuppressive agent;  interferon;  interferon receptor;  lupus anticoagulant;  mycophenolate mofetil;  obinutuzumab;  prednisolone;  rivaroxaban;  RNA;  RNA binding protein;  voclosporin, algorithm;  American College of Rheumatology criteria;  Article;  classification;  clinical assessment tool;  disease activity;  European League Against Rheumatism;  human;  organization;  pathophysiology;  phenotype;  prophylaxis;  proteinuria;  rheumatologist;  screening;  systemic lupus erythematosus;  Europe;  medical society;  practice guideline;  systemic lupus erythematosus;  United States, Europe;  Humans;  Lupus Erythematosus, Systemic;  Practice Guidelines as Topic;  Societies, Medical;  United States
TODO - null
ER -